Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease

Terecita D. Yule, Mark B. Roth, Kimberly Dreier, Anthony F. Johnson, Melissa Palmer-Densmore, Kris Simmons, Robert Fanton

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.

Original languageEnglish (US)
Pages (from-to)720-729
Number of pages10
JournalVaccine
Volume15
Issue number6-7
DOIs
StatePublished - Apr 1 1997
Externally publishedYes

Fingerprint

Cypovirus 2
Canine Parvovirus
Carnivore protoparvovirus 1
acute phase proteins
Acute-Phase Proteins
puppies
Vaccines
vaccines
neutropenia
Animal Diseases
Lymphopenia
sheds
animal diseases
Infection
Neutropenia
infection
flow cytometry
neutrophils
leukocytes
Flow Cytometry

Keywords

  • CD4-neutrophil
  • acute phase proteins
  • canine parvovirus vaccine
  • leukopenia

Cite this

Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. / Yule, Terecita D.; Roth, Mark B.; Dreier, Kimberly; Johnson, Anthony F.; Palmer-Densmore, Melissa; Simmons, Kris; Fanton, Robert.

In: Vaccine, Vol. 15, No. 6-7, 01.04.1997, p. 720-729.

Research output: Contribution to journalArticle

Yule, Terecita D. ; Roth, Mark B. ; Dreier, Kimberly ; Johnson, Anthony F. ; Palmer-Densmore, Melissa ; Simmons, Kris ; Fanton, Robert. / Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. In: Vaccine. 1997 ; Vol. 15, No. 6-7. pp. 720-729.
@article{9cc65635948148d4aa2d3c48d71c5a6a,
title = "Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease",
abstract = "Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.",
keywords = "CD4-neutrophil, acute phase proteins, canine parvovirus vaccine, leukopenia",
author = "Yule, {Terecita D.} and Roth, {Mark B.} and Kimberly Dreier and Johnson, {Anthony F.} and Melissa Palmer-Densmore and Kris Simmons and Robert Fanton",
year = "1997",
month = "4",
day = "1",
doi = "10.1016/S0264-410X(96)00232-0",
language = "English (US)",
volume = "15",
pages = "720--729",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6-7",

}

TY - JOUR

T1 - Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease

AU - Yule, Terecita D.

AU - Roth, Mark B.

AU - Dreier, Kimberly

AU - Johnson, Anthony F.

AU - Palmer-Densmore, Melissa

AU - Simmons, Kris

AU - Fanton, Robert

PY - 1997/4/1

Y1 - 1997/4/1

N2 - Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.

AB - Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.

KW - CD4-neutrophil

KW - acute phase proteins

KW - canine parvovirus vaccine

KW - leukopenia

UR - http://www.scopus.com/inward/record.url?scp=0030938648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030938648&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(96)00232-0

DO - 10.1016/S0264-410X(96)00232-0

M3 - Article

C2 - 9178474

AN - SCOPUS:0030938648

VL - 15

SP - 720

EP - 729

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6-7

ER -